<DOC>
	<DOCNO>NCT01835470</DOCNO>
	<brief_summary>The purpose study assess efficacy Abatacept intravenous administration Japanese child adolescent active juvenile idiopathic arthritis history inadequate response intolerance Methotrexate biologics</brief_summary>
	<brief_title>Efficacy , Safety , Pharmacokinetics Immunogenicity Study Abatacept Administered Intravenously Treat Active Polyarticular-course Juvenile Idiopathic Arthritis Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subjects history inadequate therapeutic response intolerance opinion examine physician least one biologics Methotrexate ( MTX ) . Diagnosis Juvenile Idiopathic Arthritis ( JIA ) International League Associations Rheumatology ( ILAR ) criterion oligoarticular , polyarticular Rheumatoid Factor ( RF+ ) , polyarticular ( RF ) , systemic polyarticularcourse . Men woman , age 4 17 year , inclusive enrollment . Subjects must history least 5 joint active disease must currently active articular disease define : 1 . ≥2 active joint ( e.g . presence swelling , swell present , limitation motion ( LOM ) accompany pain , tenderness , ) screen Week 0 ( Day 1 ) . 2 . ≥2 joint LOM screen Week 0 ( Day 1 ) . Systemic onset JIA follow manifestation within last 6 month prior enrollment : intermittent fever due JIA , rheumatoid rash , hepatosplenomegaly , pleuritis , pericarditis , macrophage activation syndrome . Presence rheumatic disease major chronic infectious/inflammatory/immunologic disease ( e.g . inflammatory bowel disease , psoriatic arthritis , spondyloarthropathy , hypogammaglobulinemia , systemic lupus erythematosus , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>